CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial
Dec 28, 2022
- CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancers
- CNS’s flagship drug candidate is called Berubicin, a product initially developed by another company with encouraging small-population results in 2006, and CNS is expanding the testing with expectations of eventually delivering an innovative new GBM treatment to market
- The company aims to enroll more than 200 patients in its global Berubicin trial on a 2:1 randomization schema comparing Berubicin-treated patients to those receiving second-line standard of care chemotherapy agent lomustine
- The company recently reported that patient enrollment has risen to 67 across its varied sites, with plans to provide an interim analysis of the trials’ progress in mid-2023
A Phase 2, globally sited clinical trial evaluating the potential efficacy of a promising brain cancer drug candidate against deadly glioblastoma (“GBM”) tumors is proceeding apace with a variety of patient profiles, affirming the drug developer’s confidence in its product.
In a Dec. 8 news release, CNS Pharmaceuticals (NASDAQ: CNSP) reported that 67 patients have enrolled in the potentially pivotal study comparing drug candidate Berubicin’s effectiveness to…
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
More News
BizDataDive: Why does a new drug require joint R&D?
In this episode, we explore why drug development knows no borders.
Explainer: Where do China-US economic and trade ties stand?
Chinese Vice Premier He Lifeng is leading a delegation to the United States for economic and trade consultations with the US side from September 19 to 23.
Billionaire Man United owner loses moral high ground after tax exile, Labour chair says
The billionaire businessman told the BBC he has lost confidence in the UK due to a combination of high taxes and high immigration.
US debt, physical constraints, and the restructuring of global capital
Global monetary tightening, energy supply disruptions and trade policy changes are creating structural cost pressures and capital reallocations across the global economy. These pressures are accelerating shifts toward local-currency financing, alternative debt markets and industrial transformation, particularly across emerging economies.
What to Do If You’re Laid Off and Too Young for Medicare
At best, older, laid-off workers will struggle to find health insurance that bridges the years before they qualify for Medicare at age 65.
Chiltern Railways renationalised after 30 years
It joins Great British Railways as part of government plans to save money and improve services.
China‑ASEAN economic cooperation benefits the world
Closer economic integration between China and ASEAN is unlocking greater growth potential. The ongoing upgrading of the China‑ASEAN free‑trade framework will further boost trade, bringing benefits to the world, according to Rosdiana Murtiningsih, Indonesia's alternate permanent representative to the FAO.
Family shares hidden cost of cancer care
Maya, 13, from Hythe in Kent, was diagnosed with neuroblastoma when she was three.
In China, A.I. Is Moving Forward While the Economy Lags Behind
As Xi Jinping arrives in the United States this week for a state visit, China’s advances in artificial intelligence will be in the air. Less discussed: China’s economy in its worst shape in decades.
Rivian C.E.O. RJ Scaringe Has Some Ideas for How to Make More Cars in America
RJ Scaringe thinks it will take robots, tariffs and diplomacy to maintain a manufacturing base in the United States.
Mistakes? We’ve Made a Few
For most of its life, The New York Times has tried to correct its errors. These efforts have not always been perfect.
As the Rich Buy Bigger Boats, Private Equity Is Investing in the Booming Marina Business
The private equity firm Blackstone now owns more marinas than anyone in the world.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.